Valuation: Lexeo Therapeutics, Inc.

Market Cap 278M 244M 230M 210M 393M 26.66B 396M 2.76B 1.07B 13.62B 1.04B 1.02B 43.77B P/E 2026 *
-2.79x
P/E 2027 * -2.47x
Enterprise Value 100M 88.12M 83.23M 75.85M 142M 9.63B 143M 996M 386M 4.92B 377M 369M 15.8B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.36%
Yield 2026 *
-
Yield 2027 * -
1 day-1.03%
1 week-19.29%
Current month-28.78%
1 month-33.92%
3 months-27.87%
6 months-40.73%
Current year-65.86%
1 week 3.32
Extreme 3.32
4.34
1 month 3.32
Extreme 3.32
5.11
Current year 3.32
Extreme 3.32
10.75
1 year 3.32
Extreme 3.32
10.99
3 years 1.45
Extreme 1.45
22.33
5 years 1.45
Extreme 1.45
22.33
10 years 1.45
Extreme 1.45
22.33
Manager TitleAgeSince
Chief Executive Officer 46 31/12/2019
Director of Finance/CFO 50 14/08/2025
Chief Operating Officer 47 01/01/2026
Director TitleAgeSince
Director/Board Member 46 31/12/2019
Chairman 72 31/12/2020
Director/Board Member 61 31/10/2020
Date Insider Type Main position Quantity % Market Cap. Importance
18/08/26 Sell

Chief Executive Officer

-3,345 0.0043%
18/08/26 Sell

Chief Operating Officer

-1,304 0.0017%
18/08/26 Sell

Chief Financial Officer

-4,117 0.0052%
Change 5-day change 1-year change 3-year change Capi.($)
-1.03%-19.29%-47.85% - 278M
-3.30%+1.19%+54.62%+104.15% 71.94B
+1.25%-3.01%+40.12%+77.12% 59.35B
+2.12%+5.79%+32.63%+24.27% 27.16B
-3.75%-2.48%-13.69%+353.96% 26.54B
-0.49%+3.24%+1.11%-3.83% 24.93B
+0.40%+0.75%+22.91%-9.68% 20.61B
-1.70%-3.35%+146.86%+325.69% 15.03B
+0.21%+1.21%-6.26%+493.02% 14.2B
+0.12%-0.79%+49.65%+165.23% 14.36B
Average -0.62%-2.00%+28.01%+169.99% 27.44B
Weighted average by Cap. -0.84%-0.26%+37.00%+131.69%

Financials

2026 *2027 *
Net sales - -
Net income -104M -91.03M -85.97M -78.35M -147M -9.94B -148M -1.03B -398M -5.08B -389M -381M -16.32B -130M -114M -108M -98.2M -184M -12.46B -185M -1.29B -499M -6.37B -488M -478M -20.46B
Net Debt -178M -156M -147M -134M -251M -17.03B -253M -1.76B -683M -8.7B -667M -653M -27.96B -305M -268M -253M -231M -432M -29.26B -435M -3.03B -1.17B -14.95B -1.15B -1.12B -48.04B
Logo Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).
Employees
63
Date Price Change Volume
25/09/26 US$3.390 0.00% 290,224
24/09/26 US$3.390 -3.69% 1,485,054
23/09/26 US$3.520 -13.51% 2,425,385
22/09/26 US$4.070 -0.25% 3,092,290
21/09/26 US$4.080 -2.86% 854,779
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
3.390USD
Average target price
20.30USD
Spread / Average Target
+498.82%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LXEO Stock